Wetzlar

Paige and Leica Biosystems Partner to Expand Access to Computational Pathology Products for Pathology and Oncology Research

Retrieved on: 
Thursday, April 22, 2021
Technology, Biotechnology, Health, Other Health, Radiology, Surgery, Oncology, Other Science, Other Technology, Research, Medical devices, General Health, Science, Data management, Optics, Leica Biosystems, Wetzlar, Microscopy, Leica Camera, Digital pathology, Ruo

b'Paige , a global leader in AI-based digital diagnostics, and Leica Biosystems , a globally recognized cancer diagnostics and workflow solution leader, today announced a strategic partnership to expand access to computational pathology products for clinical and translational research.

Key Points: 
  • b'Paige , a global leader in AI-based digital diagnostics, and Leica Biosystems , a globally recognized cancer diagnostics and workflow solution leader, today announced a strategic partnership to expand access to computational pathology products for clinical and translational research.
  • Leica Biosystems will distribute Paige\xe2\x80\x99s research-use-only (RUO) computational pathology products, starting with Paige Prostate RUO, that identify areas of interest in tumor tissue and help researchers quantify and subtype tissue more efficiently and objectively.
  • This software will be paired with Leica Biosystems digital pathology platform including slide image scanners and image management software.
  • Additional detection efforts will focus on other indications.\n\xe2\x80\x9cWe are excited to partner with Leica Biosystems in our mutual goal to define the future of cancer research through the expanded access of computational pathology products for research,\xe2\x80\x9d said Leo Grady, Ph.D., Chief Executive Officer of Paige.

North America Digital Pathology Market Report 2021: Increasing Prevalence of Chronic Diseases / Higher Cost-Efficiency / Rapid Technological Advancement

Retrieved on: 
Wednesday, March 10, 2021
Medicine, Articles, Biology, Leica Biosystems, Wetzlar, Digital pathology, Cancer, Disease, Pathology

The North America digital pathology market size is expected to reach USD 593.9 million by 2028.

Key Points: 
  • The North America digital pathology market size is expected to reach USD 593.9 million by 2028.
  • The market is predominantly driven by the growing prevalence of chronic diseases such as cancer.
  • As a consequence of the high prevalence of cancer, pathologists require data that facilitate personalizing therapy for patients.
  • The market is dominated by few players such as Philips and Leica Biosystems that hold a majority of the revenue.

FDA Expands Leica Biosystems Enforcement Discretion Enabling Remote Diagnosis Using Aperio WebViewer and Aperio AT2 Scanners During COVID-19 Crisis

Retrieved on: 
Friday, April 24, 2020
Leica Biosystems, Wetzlar, States of Germany, Optics, Leica, Microscopy, Digital pathology, Leica Camera, Pathology, Hesse

VISTA, Calif., April 24, 2020 /PRNewswire/ --Leica Biosystems, the global leader in pathology workflow solutions, today announced it has received additional notification from the U.S. Food & Drug Administration (FDA) about its intention to exercise enforcement discretion when the Aperio WebViewer, a web-based viewing software within Aperio eSlide Manager , is used for remote diagnosis with images acquired on either Aperio AT2 or Aperio AT2 DX digital pathology scanners during the COVID-19 emergency.

Key Points: 
  • VISTA, Calif., April 24, 2020 /PRNewswire/ --Leica Biosystems, the global leader in pathology workflow solutions, today announced it has received additional notification from the U.S. Food & Drug Administration (FDA) about its intention to exercise enforcement discretion when the Aperio WebViewer, a web-based viewing software within Aperio eSlide Manager , is used for remote diagnosis with images acquired on either Aperio AT2 or Aperio AT2 DX digital pathology scanners during the COVID-19 emergency.
  • In response to the COVID-19 pandemic, this application will allow Pathologists maximum flexibility to safely view and diagnose Pathology cases from remote locations, including home offices, using a consumer PC and monitor.
  • "Keeping our customers safe during the COVID-19 response while also enabling them to maintain a high standard of patient care is the number one priority for us right now," stated Melissa Aquino, Presidentof Leica Biosystems.
  • Leica Biosystems ( LeicaBiosystems.com ) is a global leader in workflow solutions and automation, integrating each step in the workflow.

Leica Biosystems Receives FDA's Enforcement Discretion For Use Of Aperio ImageScope DX Viewing Software For Remote Diagnosis During COVID-19 Emergency

Retrieved on: 
Friday, April 3, 2020
Leica Biosystems, Wetzlar, Leica, States of Germany, Leica Camera, Hesse, Companies

VISTA, Calif., April 3, 2020 /PRNewswire/ -- Leica Biosystems, the global leader in pathology workflow solutions, today announced it has received notification from the U.S. Food & Drug Administration (FDA) that its Aperio ImageScope DX Viewer with images acquired on the Aperio AT2 DX Scanner can be used for remote diagnosis under emergency use.

Key Points: 
  • VISTA, Calif., April 3, 2020 /PRNewswire/ -- Leica Biosystems, the global leader in pathology workflow solutions, today announced it has received notification from the U.S. Food & Drug Administration (FDA) that its Aperio ImageScope DX Viewer with images acquired on the Aperio AT2 DX Scanner can be used for remote diagnosis under emergency use.
  • This application will allow Pathologists to safely view and diagnose Pathology cases from remote locations in response to the COVID-19 pandemic .
  • "This remote use capability will be transformative and help alleviate the pressure that the emergence of the COVID-19 outbreak has put on healthcare facilities," stated Melissa Aquino, Presidentof Leica Biosystems.
  • Leica Biosystems ( LeicaBiosystems.com ) is a global leader in workflow solutions and automation, integrating each step in the workflow.

Transforming Conventional to Digital Pathology, Leica Biosystems Introduces Case Management Software to Support Aperio AT2 DX System for Primary Diagnosis

Retrieved on: 
Monday, March 2, 2020
Leica Biosystems, Wetzlar, Microscopy, Pathology, Digital pathology

"Digital pathology has entered the clinical environment with the goal of improving efficiencies, streamlining laboratory workflows, and expanding pathology services," stated Dan Schrock, Vice President, Clinical Affairs for Leica Biosystems.

Key Points: 
  • "Digital pathology has entered the clinical environment with the goal of improving efficiencies, streamlining laboratory workflows, and expanding pathology services," stated Dan Schrock, Vice President, Clinical Affairs for Leica Biosystems.
  • Aperio Path DX offers tailored software workflows for histotechnicians and pathologists, including quality control, case assembly, assignment and review.
  • It provides a secure digital workstream from the pathology lab to the pathologist's desk, supporting the on-screen primary diagnosis capabilities of the Aperio AT2 DX System.
  • Leica Biosystems ( LeicaBiosystems.com ) is a cancer diagnostics company and a global leader in workflow solutions, offering the most comprehensive portfolio from biopsy to diagnosis.

Sectra and Leica Biosystems Partner to Pursue FDA Clearance for an Integrated Clinical Digital Pathology Solution

Retrieved on: 
Monday, December 2, 2019
Leica Biosystems, Wetzlar, Optics, States of Germany, Microscopy, Leica, Leica Camera, Digital pathology, Hesse

SHELTON, Connecticut, Dec. 2, 2019 /PRNewswire/ --International medical imaging IT and cybersecurity company Sectra (STO: SECT B) and Leica Biosystems announce collaboration for an integrated clinical pathology solution.

Key Points: 
  • SHELTON, Connecticut, Dec. 2, 2019 /PRNewswire/ --International medical imaging IT and cybersecurity company Sectra (STO: SECT B) and Leica Biosystems announce collaboration for an integrated clinical pathology solution.
  • "Leveraging Leica Biosystems' existing 510(k) clearance for its Aperio AT2 DX scanner, and extending it with the Sectra Digital Pathology Solution for hospitals and health systems, enable us to deliver a clinical solution to meet the needs of the truly integrated digital hospitals of today and tomorrow," says Torbjrn Kronander, Founder & CEO of Sectra.
  • "This is an exciting and important advancement for the clinical pathology industry and a huge step forward in clinical usability."
  • Leica Biosystems is committed to investing in the development of Aperio Digital Pathology software, image analysis and hardware solutions.

Leica Biosystems and Sectra Partner to Pursue FDA Clearance for an Integrated Clinical Digital Pathology Solution

Retrieved on: 
Monday, December 2, 2019
Leica Biosystems, Wetzlar, Optics, States of Germany, Microscopy, Leica Camera, Digital pathology, Hesse

The goal is for the integrated clinical digital pathology solution to address the clinical needs of enterprise level customers such as academic medical centers, clinical research organizations and large hospital networks.

Key Points: 
  • The goal is for the integrated clinical digital pathology solution to address the clinical needs of enterprise level customers such as academic medical centers, clinical research organizations and large hospital networks.
  • "Leveraging Leica Biosystems existing 510(k) clearance for its Aperio AT2 DX scanner, and extending it with the Sectra digital pathology solution for hospitals and health systems, would enable us to deliver a clinical solution to meet the needs of the truly integrated digital hospitals of today and tomorrow," said Torbjrn Kronander, Founder & CEO of Sectra.
  • "This will be an exciting and important advancement for the clinical pathology industry and a huge step forward in clinical usability."
  • Leica Biosystems is committed to investing in the development of Aperio Digital Pathology software, image analysis and hardware solutions.

Leica Biosystems and Sectra Partner to Pursue FDA Clearance for an Integrated Clinical Digital Pathology Solution

Retrieved on: 
Monday, December 2, 2019
Leica Biosystems, Wetzlar, Optics, States of Germany, Microscopy, Leica Camera, Digital pathology, Hesse

The goal is for the integrated clinical digital pathology solution to address the clinical needs of enterprise level customers such as academic medical centers, clinical research organizations and large hospital networks.

Key Points: 
  • The goal is for the integrated clinical digital pathology solution to address the clinical needs of enterprise level customers such as academic medical centers, clinical research organizations and large hospital networks.
  • "Leveraging Leica Biosystems existing 510(k) clearance for its Aperio AT2 DX scanner, and extending it with the Sectra digital pathology solution for hospitals and health systems, would enable us to deliver a clinical solution to meet the needs of the truly integrated digital hospitals of today and tomorrow," said Torbjrn Kronander, Founder & CEO of Sectra.
  • "This will be an exciting and important advancement for the clinical pathology industry and a huge step forward in clinical usability."
  • Leica Biosystems is committed to investing in the development of Aperio Digital Pathology software, image analysis and hardware solutions.

Delivering Greater Throughput And Decreased Turnaround Time For Research Labs Is The Focus Of Leica Biosystems Next Generation Digital Pathology Scanner

Retrieved on: 
Friday, August 9, 2019
Articles, Business, Optics, Leica Biosystems, Wetzlar, Microscopy, Leica, Workflow, Digital pathology, Leica Camera, Applied Spectral Imaging

VISTA, Calif., Aug. 9, 2019 /PRNewswire/ -- Leica Biosystems, the global leader in pathology workflow solutions, announced today that it has launched the Aperio GT 450, its next generation digital pathology scanner.

Key Points: 
  • VISTA, Calif., Aug. 9, 2019 /PRNewswire/ -- Leica Biosystems, the global leader in pathology workflow solutions, announced today that it has launched the Aperio GT 450, its next generation digital pathology scanner.
  • This new technology allows customers performing research to scale up digital pathology to meet ever increasing slide volume demands.
  • "The Aperio GT 450 has demonstrated, in a workflow study at our laboratories, substantial increases in throughput while dramatically reducing hands on time for our histotechnicians.
  • Leica Biosystems ( LeicaBiosystems.com ) is a global leader in workflow solutions and automation, integrating each step in the workflow.

Deep Lens Appoints Kevin Whiteley as Vice President of Provider Sales

Retrieved on: 
Thursday, July 11, 2019
Biotechnology, Technology, Health, Oncology, Research, Medical devices, Software, Science, Data management, Clinical trials, Leica Biosystems, Wetzlar, Camera lens, Leica Camera, States of Germany, Hesse, Optics, VIPER, Deep Lens

Deep Lens, Inc. , an AI-driven digital pathology company focused on clinical trial recruitment at the time of diagnosis, announced today the company has appointed Kevin Whiteley as Vice President of Provider Sales.

Key Points: 
  • Deep Lens, Inc. , an AI-driven digital pathology company focused on clinical trial recruitment at the time of diagnosis, announced today the company has appointed Kevin Whiteley as Vice President of Provider Sales.
  • Whiteley is a diagnostics and medical device executive with extensive experience in general management, marketing management, sales leadership, and business development.
  • Prior to joining Deep Lens, Whiteley was the Vice President, Market and Business Development for Leica Biosystems.
  • View the full release here: https://www.businesswire.com/news/home/20190711005235/en/
    Kevin Whiteley, Vice President of Provider Sales at Deep Lens, Inc., an AI-driven digital pathology company focused on clinical trial recruitment at the time of diagnosis (Photo: Business Wire)
    Kevin has more than 10 years of prominent experience in digital pathology, leading global market development, sales, and strategic partnerships, said Simon Arkell, president and co-founder of Deep Lens.